Sector News

Medtech industry condemns Russia’s invasion of Ukraine

March 13, 2022
Life sciences

The medical device industry is voicing and lending support to the people of Ukraine amid the country’s war with Russia.

While medtech companies aren’t going as far as biotech leaders, many of whom have vowed to break ties with Russian companies over Russia’s invasion of Ukraine, the industry is condemning Russian President Vladimir Putin’s attack on its neighbor.

AdvaMed, a medtech lobby group, said in a statement late last week that it condemned “the actions that have resulted in such devastation and loss of human life in Ukraine” and its member companies “are committed to mobilizing our industry to help those who are suffering as a result of this invasion.”

The group said it is working with the U.S. government and non-governmental organizations to assess the need for medical supplies in Ukraine. The group has created a resource list on its website to help coordinate the distribution of critical items as part of the humanitarian aid effort.

Siemens Healthineers said in an emailed statement to MedTech Dive that the company “strongly condemns the invasion by Russian forces of Ukraine, a sovereign European nation, in clear violation of international law,” adding that it is “moved by the courage of the Ukrainian people.”

The fighting has had an impact on the normal supply chain. A spokesperson for MedTech Europe said in an emailed statement that the “normal logistics chain towards Ukraine are being disrupted since the beginning of the crisis, with main routes being cut.”

“As the medical technology industry, we are working together with civil defense mechanisms to ensure insofar as possible the availability of medical supplies,” the group stated.

The MedTech Europe spokesperson said that the group is still assessing the impact of sanctions on the supply and delivery of medical devices and technologies. READ MORE

By Ricky Zipp, Greg Slabodkin

Source: biopharmadive.com

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach